SCHEMBL4136835

SCHEMBL4136835

c1cncc(-c2ccc(N3CCC4(CC3)CCN(C3CCC3)CC4)nn2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 2/20 0.46
CYP2C9 P11712 3/20 0.43
CYP3A4 P08684 3/20 0.43
CYP2D6 P10635 3/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 2/20 0.43
CHRNA7 P36544 1/20 0.42
KDM2B Q8NHM5 1/20 0.42
P4HTM Q9NXG6 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
KMT2A Q03164 1/20 0.38
KCNH2 Q12809 1/20 0.37
MAP2K5 Q13163 1/20 0.37
RIOK2 Q9BVS4 1/20 0.37
PORCN Q9H237 1/20 0.37
ACHE P22303 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CDK4 P11802 1/20 0.37
TRPV6 Q9H1D0 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931859 0.94 SCD (0.42) SCDCYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL4136820 0.87 HRH3 (0.37) SCDKDM2BHRH3KCNH2
SCHEMBL4130690 0.87 CHRNA7 (0.46) CHRNA7HRH3KMT2AKDM4EALDH1A1
SCHEMBL4134856 0.86 CSNK1E (0.37) SCDCYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL1742505 0.85 CYP2C9 (0.52) SCDCYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL4134644 0.84 CYP2C9 (0.43) CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2
SCHEMBL4130331 0.84 CYP3A4 (0.48) CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2
SCHEMBL4140809 0.84 KDM2B (0.45) CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2
SCHEMBL1743024 0.84 CYP2C9 (0.51) SCDCYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL4934240 0.83 KDM4E (0.38) CYP3A4HRH3KDM4ECDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 SCD 4210/4885CYP2C9 1705/4885CYP3A4 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.